Company Overview
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.
Recent News
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
SCYNEXIS to Participate in Upcoming Investor Conferences
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Stock Overview
Symbol
SCYX
Exchange
Nasdaq
Market Cap
45.77m
Last Price
$4.60
52-Week Range
$3.53 - $10.48
09/14/2026 08:00 PM EDT